TREATMENT OF ERECTILE DYSFUNCTION WITH PHOSPHODIESTERASE TYPE 5 INHIBITOR (PDE5 INH) IN MALE PARTNER OF WOMEN WITH VAGINISMUS

被引：0
|
作者：
Ozkara, H. [1 ]
Akkus, E. [1 ]
Dinc, S. [1 ]
Alici, B. [1 ]
Tek, B. [1 ]
机构：
[1] Istanbul Univ, Istanbul, Turkey
来源：
JOURNAL OF SEXUAL MEDICINE | 2011年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：437 / 438
页数：2
相关论文
共 50 条
  • [31] PDE5 inhibitors: targeting erectile dysfunction in diabetics
    Francis, Sharron H.
    Corbin, Jackie D.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2011, 11 (06) : 683 - 688
  • [32] Mechanisms of action of PDE5 inhibition in erectile dysfunction
    J D Corbin
    [J]. International Journal of Impotence Research, 2004, 16 : S4 - S7
  • [33] Phosphodiesterase type 5 (PDE5) inhibition and cognitive enhancement
    Devan, BD
    Duffy, KB
    Bowker, JL
    Bharati, IS
    Nelson, CM
    Daffin, LW
    Spangler, EL
    Ingram, DK
    [J]. DRUGS OF THE FUTURE, 2005, 30 (07) : 725 - 736
  • [34] Evidence for pharmacological contamination of herbal erectile function products with type 5 phosphodiesterase (PDE5) inhibitors
    Fleshner, NE
    Harvey, M
    Adomat, H
    Wood, C
    Hersey, K
    Guns, E
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04): : 314 - 314
  • [35] The basics of phosphodiesterase type 5 (PDE5) inhibition in urology
    Becker, A. J.
    Ueckert, S.
    Stief, C. G.
    [J]. UROLOGE, 2008, 47 (12): : 1582 - 1587
  • [36] Safety and efficacy of avanafil, a new phosphodiesterase type-5 (PDE-5) inhibitor for treating erectile dysfunction
    Kaufman, JM
    Dietrich, JW
    [J]. JOURNAL OF UROLOGY, 2006, 175 (04): : 299 - 299
  • [37] Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5)
    F Salvi
    R Sarzani
    R Giorgi
    G Donatelli
    F Pietrucci
    A Micheli
    M Baldoni
    D Minaroli
    P Dessì-Fulgheri
    M Polito
    G Muzzonigro
    A Rappelli
    [J]. International Journal of Impotence Research, 2004, 16 : 412 - 417
  • [38] Rigiscan evaluation of TA-1790, a novel PDE5 inhibitor for the treatment of men with erectile dysfunction
    Lewis, RW
    Hellstrom, WJG
    Gittelman, M
    McMurray, JG
    Padma-Nathan, H
    Young, J
    Steidle, C
    Peterson, CA
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04): : 316 - 316
  • [39] Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5)
    Salvi, F
    Sarzani, R
    Giorgi, R
    Donatelli, G
    Pietrucci, F
    Micheli, A
    Baldoni, M
    Minaroli, D
    Dessì-Fulgheri, P
    Polito, M
    Muzzonigro, G
    Rappelli, A
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2004, 16 (05) : 412 - 417
  • [40] Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability
    Wang, Run
    Burnett, Arthur L.
    Heller, Warren H.
    Omori, Kenji
    Kotera, Jun
    Kikkawa, Kohei
    Yee, Shiyin
    Day, Wesley W.
    DiDonato, Karen
    Peterson, Craig A.
    [J]. JOURNAL OF SEXUAL MEDICINE, 2012, 9 (08): : 2122 - 2129
12345